Blogs & News

In recent developments at Stony Brook University's Department of Chemistry, Dr. Iwao Ojima and his team have made significant strides in the development of next-generation anti-cancer agents. One standout compound, NE-DHA-SBT-1214, a second-generation taxane conjugate formulated in nanoemulsion, has shown exceptional promise against solid tumors, particularly colorectal cancer. Originally licensed to TargaGenix, Inc., in 2016, NE-DHA-SBT-1214 has undergone rigorous development to enhance its formulation, address toxicity concerns, and improve in vivo efficacy. Now, with substantial investment from TVM Capital Life Science, TargaGenix aims to advance this compound towards clinical trials, potentially revolutionizing cancer treatment strategies.

Taxanes, a class of drugs renowned for their efficacy against solid tumors, include widely used agents like paclitaxel and docetaxel. Despite their effectiveness, issues such as multidrug resistance (MDR) and adverse effects have limited their utility. NE-DHA-SBT-1214 represents a novel approach, leveraging a second-generation taxane conjugated with DHA (a component of omega-3 fish oil) in a nanoemulsion. This formulation not only enhances drug delivery to tumors through nano-sized particles but also demonstrates potent activity against MDR and cancer stem cells (CSCs), addressing critical challenges in cancer therapy.

Colorectal cancer, known for its resistance to multiple drugs, serves as a primary target for NE-DHA-SBT-1214. Promising preclinical results also highlight its potential for treating pancreatic and prostate cancers. For instance, combination therapies involving NE-DHA-SBT-1214 with PLD-1 antibodies have shown superior outcomes compared to current standards for pancreatic cancer treatment.

The nanoemulsion technology underpinning NE-DHA-SBT-1214's formulation originated from research by Dr. Mansoor Amiji at Northeastern University. This technology facilitates selective drug delivery to tumors, capitalizing on the Enhanced Permeability and Retention (EPR) effect typical of nano-sized particles. Such precise targeting not only enhances therapeutic efficacy but also minimizes systemic toxicity, a common concern with conventional cancer treatments.

"This innovative taxane conjugate represents a culmination of decades of research aimed at combating challenging cancers like colorectal and pancreatic cancers," remarks Dr. Iwao Ojima, Director of the Institute of Chemical Biology & Drug Discovery. "Entering clinical trials marks a significant milestone in translating basic scientific discoveries into potential clinical benefits for cancer patients."

The collaboration between Stony Brook University, TargaGenix, and TVM Capital Life Science underscores the critical role of academic-industry partnerships in advancing medical innovation. With a commitment of up to $24 million, TVM aims to propel NE-DHA-SBT-1214 through pivotal clinical development stages, aiming to establish it as a new standard of care in oncology.

James E. Egan, CEO of TargaGenix and a Stony Brook University alumnus, emphasizes, "We are thrilled to have the robust support of TVM, enabling us to accelerate the development of this potentially transformative molecule." This sentiment is echoed by Dr. Peter Igarashi, Dean of the Renaissance School of Medicine at Stony Brook University, highlighting the profound impact of collaborative research efforts on advancing cancer therapeutics.